A discreet chemist behind a 20th-century symbol
Few molecules have carried as much symbolic weight as LSD. It is associated with the 1960s, with psychedelia, with the promise of expanding the mind, and, almost simultaneously, with fear and prohibition. Behind all that cultural noise is a much more sober figure: a methodical chemist, a reader of Goethe, and an amateur plant observer who spent almost his entire working life in the same Basel laboratory.
Albert Hofmann never quite fit the role of “father of psychedelia” that the press assigned to him. He was as uncomfortable with the recreational and mass use of his discovery as he was interested in its potential value in psychiatry and contemplative experience. That tension—between the laboratory and the myth—is the best entry point into his story.
From Baden to the Sandoz laboratories
Hofmann was born on January 11, 1906, in Baden, in the Swiss canton of Aargau, into a humble family left in a delicate situation after his father’s early death. As the eldest son, he balanced his adolescence with work in a tool factory. His true interest was the chemistry of living things: plants and animals.
He studied chemistry at the University of Zurich and earned his doctorate with a thesis on the structure of chitin, one of the components of fungal cell walls. He then joined the research laboratory at Sandoz (now part of Novartis) in Basel, working in the area of natural active ingredients under Professor Arthur Stoll. He remained there until his retirement in 1971. During those years, he contributed to the development of drugs—analgesics and compounds used in obstetrics and neurology—that consolidated Sandoz as a major international pharmaceutical company.
Ergot as a starting point
Much of Hofmann’s work revolved around ergot, a parasitic fungus of rye whose effects on the human body had been known since ancient times: collective poisonings with delirium and intense pain, known as “St. Anthony’s fire.” Its alkaloids were already used in medicine, for example, for postpartum hemorrhaging and, later, for certain types of headaches.
The chemist’s goal was to isolate and produce these active ingredients with purity and controlled dosages. That work produced, among others, the alkaloid marketed as Methergin, which is still used in hospitals today. The key was lysergic acid, the common core of ergot alkaloids: once obtained synthetically, it opened the door to a multitude of derivatives.
One of these was lysergic acid diethylamide, synthesized in 1938 and cataloged as sample number 25: hence the name LSD-25. Hofmann was looking for a circulatory stimulant (an analeptic); tests on animals did not show that effect, and the compound was shelved. Nothing more was done with it until 1943.
April 16 and 19, 1943: The discovery
In the spring of 1943, Hofmann synthesized the molecule again. On April 16, he noticed a strange malaise and had to leave the laboratory; he suspected that some of the substance had been absorbed through his skin. In his diary, he described very vivid and colorful images, “like a kaleidoscope,” which dissipated in a couple of hours.
Intrigued, three days later he decided to test it in a controlled manner. On the afternoon of April 19, he ingested 250 micrograms, an amount he considered too small to have an effect and which we now know is several times the active dose. The bike ride home—which psychedelic culture would later celebrate as “Bicycle Day”—was an agonizing experience: a sensation of dissociation, fear of having lost his mind, and the loss of habitual references. Only hours later did the episode shift into a luminous calm and a renewed sense of wonder at the mundane.
Beyond the anecdote, what was relevant for chemistry was confirming that no other known substance acted on the nervous system at such a minute scale. Furthermore, its acute toxicity is very low, and no direct fatal overdoses have been documented—something that should not be confused with an absence of risks: psychological harm and accidents associated with a bad setting are real.
From medicine to “problem child”
Hofmann soon sensed the interest of the discovery for psychiatry. Sandoz distributed it to medical professionals under the trade name Delysid, presenting it as a tool to explore the inner world of patients and as a potential support for states of anxiety and neurosis. Between the late 1940s and the mid-1960s, numerous studies were published, and the substance was produced industrially for clinical use.
That controlled framework was blown apart when LSD spilled over from the medical sphere and became a banner of the counterculture. Hofmann was troubled by improvised use in clubs or parties, without preparation or guidance. He compared the situation to that of the sacred plants of indigenous peoples, reserved for ritual contexts and prepared individuals. The social reaction was fierce: prohibitions, alarm, and headlines speaking of a “satanic drug.” He himself christened his discovery his “problem child.”
To that era also belongs a disturbing chapter: the interest of intelligence services and the US military, which experimented with LSD—sometimes without the subjects’ consent—looking for a “truth serum” or a weapon. According to Hofmann himself, military agents even asked him how to produce large quantities; his response was that, starting from ergot, that was unfeasible on an industrial scale.
Hofmann’s mysticism and its limits
Over the years, Hofmann’s therapeutic expectations cooled, but not his more philosophical reading of LSD. He described it as a way to question deep-seated dualisms—subject and object, mind and body—and to experience a sense of belonging to a whole. He declared himself a believer, though wary of dogmas, and placed happiness in the small things and in a life as natural as possible.
He also insisted on the importance of preparation: he recalled the stance of Aldous Huxley, who advocated for a “science of mystical experience” prior to any consumption, and returned again and again to the Eleusinian Mysteries as a model for ritual and careful use.
It is advisable to read these ideas with some distance. The narrative of “well-done sacred use versus dangerous profane use” is seductive, but it idealizes both ancient traditions and the capabilities of the molecule, shifting the focus away from what we now understand as harm reduction: context, the person’s psychological state, interactions, and mental health history weigh more than any symbolic aura. Hofmann stopped using LSD in 1972, according to him because he had already “understood the message.”
Beyond LSD
Hofmann’s name is tied to LSD, but his chemical work was broader. He studied Mexican fungi and plants used by indigenous peoples, work that led him to identify psilocybin as their active ingredient. He also isolated related compounds from ololiuqui seeds. In 1962, he traveled to Mexico with his wife, Anita, on the trail of Salvia divinorum, the “María Pastora.”
He died on April 29, 2008, at the age of 102, in his home in Burg (canton of Basel). He accumulated honorary doctorates from Harvard, Zurich, Stockholm, and Berlin, and authored works such as The Road to Eleusis—alongside Wasson and Ruck—and Insight Outlook. Regarding his longevity, he used to joke that the secret was not LSD, but fried eggs with butter.
Critical reading
Hofmann’s figure lends itself to two opposing simplifications: the guru who “opened the doors of perception” and the sorcerer’s apprentice who unleashed a danger. Both say more about the cultural climate of each era than about the person himself.
- Distinguish chemistry from myth. LSD was born in a conventional pharmaceutical research line; its symbolic weight was added by the 1960s, not the laboratory.
- “Low toxicity” is not “harmless.” The absence of known lethal overdoses coexists with real psychological risks, especially in people with psychiatric histories or in inadequate contexts.
- Renewed clinical interest requires caution. Current psychedelic trials are conducted in controlled settings, with screening, guidance, and follow-up; none of that is transferable to self-administered use.
- “Sacred use” is not a guarantee. Appealing to Eleusis or shamanism is no substitute for information, context, and harm reduction.
To delve deeper in a rigorous way, it is advisable to turn to Hofmann’s own writings and to sound academic and historical literature on LSD and psychedelic research, always contrasting sources and avoiding hagiographic accounts.
